AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) shot up 1.8% on Monday . The stock traded as high as $3.49 and last traded at $3.44, with a volume of 53,732 shares changing hands. The stock had previously closed at $3.38.

Several brokerages recently weighed in on ACRX. Stifel Nicolaus cut AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 5th. HC Wainwright restated a “buy” rating on shares of AcelRx Pharmaceuticals in a report on Monday, August 1st. Seaport Global Securities upgraded AcelRx Pharmaceuticals from an “accumulate” rating to a “buy” rating in a report on Friday, May 6th. Cowen and Company restated a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Friday, July 29th. Finally, RBC Capital Markets restated a “positive” rating and set a $6.00 target price on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 16th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $7.30.

The company’s 50-day moving average price is $3.24 and its 200-day moving average price is $3.34. The firm’s market capitalization is $156.33 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.02. The business earned $4.53 million during the quarter, compared to analyst estimates of $2.17 million. On average, equities research analysts forecast that AcelRx Pharmaceuticals Inc. will post ($0.91) earnings per share for the current fiscal year.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.